In skin carcinoma cells, EGCG increases the levels of acetylation of histone H3 and histone H4 lysine residues through HDAC inhibition, leading to the upregulation of tumor-suppressor genes (188) (Table 4, Section 2). The gene discussed is HDAC9; the disease is neoplasm.